Comparing the current results to its competitors, Alto Neuroscience Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 14.63 %, recorded in the same quarter.
Alto Neuroscience Inc 's Comment on Competition and Industry Peers
The company operates in the biopharmaceutical industry, focusing on neuropsychiatry and central nervous system (CNS) disorders. It competes with various biopharmaceutical and biotechnology companies, academic institutions, governmental agencies, and research organizations. Several competitors possess greater financial resources and more extensive experience in drug discovery, development, regulatory approval, and commercialization. The company faces competition from existing approved drugs, new market entrants, and emerging technologies. Notable competitors with approved therapies or product candidates in development for major depressive disorder, treatment-resistant depression, bipolar depression, and schizophrenia include AbbVie Inc., Atai Beckley, Inc., Axsome Therapeutics, Inc., Compass Pathways, Inc., Neumora Therapeutics, Inc., Neurocrine Biosciences, Inc., and Xenon Pharmaceuticals, Inc. Key competitive factors include efficacy, safety, convenience, price, generic competition, and reimbursement availability.
December 11, 2024
Alto Neuroscience: Progress Amidst Challenges at the 63rd Annual ACNP MeetingAlto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company dedicated to the development of innovative precision medicines for neuropsychiatric disorders, made significant waves at the 63rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held from December 8-11, 2024, in Phoenix, Arizona. This year’s ACNP meeting served as a platform for Alto to showcase its ongoing advancements in their product pipeline, particularly within the burgeoning field of precision psychiatry.The presentation at ACNP highlighted a series of strategic developments within Alto s roster of therapeutic candidat...
September 4, 2024
Alto Neuroscience Unveils Revelatory Publication: Baseline Cognitive Performance Does Not Influence Antidepressant Efficacy Mountain View, Calif. In an era...
Alzamend Neuro Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapeutics for Alzheimer's disease and other neurological disorders. Their business model revolves around conducting extensive research and clinical trials to develop groundbreaking treatments that address the underlying causes of these debilitating conditions. With a focus on creating value for patients, healthcare providers, and shareholders, they aim to bring effective therapies to market and improve the quality of life for those affected by neurodegenerative diseases.
Compass Pathways Plc is a mental healthcare company focused on developing innovative therapies for treatment-resistant depression. They are pioneering the use of psychedelic-assisted therapy to address this significant unmet medical need. With a business model centered around clinical research and drug development, their goal is to bring their therapies to market and improve the lives of patients suffering from depression.
Bright Minds Biosciences Inc is a biotechnology company that focuses on developing novel therapies for neuropsychiatric diseases. Their business model involves conducting research and development to discover and develop proprietary drug candidates, with the aim of partnering or licensing them to pharmaceutical companies for further clinical development and commercialization.
Sources:
Alto Neuroscience Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Alto Neuroscience Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
